Posts by Aaron Hata, MD, PhD
-
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
-
MET Alterations Are a Recurring Resistance Mechanism in ALK-Positive Lung Cancer
Massachusetts General Hospital Cancer Center researchers find that ALK/MET combination therapy is a rational approach to treatment of ALK-positive non-small-cell lung cancer.
Biography
Assistant Physician, Hematology and Oncology, Massachusetts General Hospital
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
